<DOC>
	<DOCNO>NCT00000641</DOCNO>
	<brief_summary>To compare effectiveness toxicity two combination drug treatment program treatment disseminate Mycobacterium avium infection HIV seropositive patient . [ Per 03/06/92 amendment : evaluate efficacy azithromycin give conjunction either ethambutol clofazimine maintenance therapy . ] Disseminated M. avium infection common systemic bacterial infection complicate AIDS United States . The prognosis patient disseminate M. avium extremely poor , particularly follow opportunistic infection associate anemia . Test tube study clinical data indicate best treatment program may include clofazimine , ethambutol , rifamycin derivative , ciprofloxacin . Test tube animal study indicate amikacin bactericidal ( bacteria destroy ) drug work well use ciprofloxacin . Its role treatment program key issue toxicity must administer parenterally ( injection intravenously ) .</brief_summary>
	<brief_title>A Phase II/III Trial Rifampin , Ciprofloxacin , Clofazimine , Ethambutol , Amikacin Treatment Disseminated Mycobacterium Avium Infection HIV-Infected Individuals .</brief_title>
	<detailed_description>Disseminated M. avium infection common systemic bacterial infection complicate AIDS United States . The prognosis patient disseminate M. avium extremely poor , particularly follow opportunistic infection associate anemia . Test tube study clinical data indicate best treatment program may include clofazimine , ethambutol , rifamycin derivative , ciprofloxacin . Test tube animal study indicate amikacin bactericidal ( bacteria destroy ) drug work well use ciprofloxacin . Its role treatment program key issue toxicity must administer parenterally ( injection intravenously ) . Patients undergo initial 2-week observation period ( day 1 - 14 ) time baseline evaluation perform type severity symptom monitor . Eligible patient randomize day 15 one two treatment program : ( 1 ) ciprofloxacin , clofazimine , ethambutol , rifampin ( take orally ) , ( 2 ) four drug plus amikacin . Only patient blood culture obtain either day 1 day 14/15 positive week 6 continue study drug . Patients receive combination therapy 24 week . Patients may indwell central venous catheter place long-term administration intravenous drug . PER 03/06/92 AMENDMENT : Newly enrol patient demonstrate complete partial clinical response end study week 10 ( 8 week drug therapy ) discontinue current regimen begin maintenance therapy azithromycin plus either ethambutol clofazimine additional 24 week . Patients demonstrate response study week 10 discontinue study therapy . Patients enrol early version protocol surpass study week 16 ( 14 week drug therapy ) continue treatment originally assign regimen study week 26 ; surpass study week 16 consider inclusion maintenance phase study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Clofazimine</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Zidovudine ( AZT ) didanosine ( ddI ) . Dideoxycytidine ( ddC ) , EPO , experimental therapy grant Treatment IND Expanded Access status , exception rifabutin . Concurrent therapy ( acute maintenance ) opportunistic infection specifically prohibit . Concurrent Treatment : Allowed : Interferonalfa . Patients must follow : HIV infection diagnosis AIDS per CDC classification . Mycobacterium avium isolate blood . Capability sign informed consent , consent guardian &lt; 18 year age . Ability willingness participate component study receive study therapy . Prior Medication : Allowed : Interferonalfa . Single drug prophylaxis Mycobacterium avium M. tuberculosis within previous 4 week . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Treatment Phase : Known suspect allergy study medication . Severe hearing loss . Maintenance Phase : Severe hearing loss . Hypersensitivity macrolides . Intolerance ethambutol clofazimine . Concurrent Medication : Excluded : Acute therapy opportunistic infection time study entry . Nephrotoxic agent amphotericin B , intravenous vancomycin , foscarnet first 4 week study therapy without specific exemption one protocol chair . Antacids within 2 hour ingestion study drug . Immunomodulators ( except interferonalfa ) antimycobacterial drug ( include quinolones aminoglycosides ) . All experimental therapy ( except ddI , ddC , experimental agent grant `` Treatment IND '' `` expand access '' status ) prohibit ( specific exemption must obtain one protocol chair ) . Patients follow exclude : Known suspect allergy study medication . Can take drug orally . Severe hearing loss , discretion investigator . Prior Medication : Excluded : Antimycobacterial drug ( include azithromycin , clarithromycin , rifamycins , quinolones , aminoglycosides ) immunomodulators ( except interferonalfa ) within 4 week prior entry , except singledrug prophylaxis specifically allow . History unreliable drug intake . Inability cooperate test procedure .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Rifampin</keyword>
	<keyword>Mycobacterium avium-intracellulare Infection</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Ethambutol</keyword>
	<keyword>Clofazimine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Amikacin</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Ciprofloxacin</keyword>
</DOC>